OPERA-01: Palazestrant vs. Standard-of-Care for ER+/HER2- MBC
Elisabeth de Kermadec will discuss the OPERA-01 phase 3 study, focusing on the efficacy of palazestrant (OP-1250) compared to standard treatments in ER+, HER2- metastatic breast cancer post endocrine therapy and CDK4/6 inhibitor resistance. We will discuss her study and review the poster “the OPERA-01 phase 3 study with us, focusing on the efficacy of palazestrant (OP-1250) compared to standard treatments in ER+, HER2- metastatic breast cancer post endocrine therapy and CDK4/6 inhibitor resistance.” which was presented at the 2024 American Society of Clinical Oncology Annual Meeting (ASCO).
Speaker
-
Elisabeth de KermadecSenior Medical Director, OlemaSenior Medical Director, Olema
Dr. Elisabeth de Kermadec is a gynecologist who specialized in breast cancer. She obtained her medical degree from the Paris V Descartes University (France) and a MPH degree from Paris Sud University (France). She completed a postdoctoral training at Dana-Farber Cancer Institute (Boston) in the laboratory of Ann Patridge, MD, MPH, where she explored fertility issues in young women with breast cancer.
Elisabeth joined Sanofi in 2020 to lead a pivotal Phase II/III clinical trial with oral SERD amcenestrant for the treatment of ER+, HER2- advanced breast cancer. During her time at Sanofi, she also worked in early clinical development leading studies in hematologic oncology. She joined Olema end-2023 as a Senior Medical Director, serving as Medical Lead of the OPERA-01 study, evaluating palazestrant for the treatment of ER+, HER2- advanced breast cancer. She aims to contribute to developing drugs that can improve the lives of patients living with breast cancer.
